(주)셀렉스라이프사이언스

News

ILIAS is the Leader of Next-Generation Exosome Therapeutics.

[ENG] 보도자료

ILIAS Biologics signs MOU with KBIO Health to improve global competitiveness in exosome therapeutics

페이지 정보

  • 작성자 : ILIAS Biologics
  • 작성일 : 20-09-11 17:21
  • 조회 : 216회

본문


10 Sep 2020

 

ILIAS Biologics signs MOU with KBIO Health to improve global competitiveness in exosome therapeutics 

 

On Thursday, Sep 10th, ILIAS Biologics Inc. signed a Memorandum of Understanding (MoU) with New Drug Development Center and Bio Pharmaceuticals Manufacturing Center of Osong Medical Innovation Foundation (KBIO Health).

The MoU is focused on collaboration for commercialization of exosome-based therapeutics. In this context, ILIAS takes charge of development of EXPLOR®, which enables loading of large therapeutic cargo proteins into the lumen of exosomes, KBIO Health is in charge of medicinal efficacy evaluation, analysis, GMP production and support of manufacturing process research to improve global competitiveness in exosome-based therapeutics.

 

Please find the link below for more information. (Korean) 

(Click)

개인정보취급방침

닫기

이메일주소무단수집거부

닫기

사이트맵

사이트맵

몬트리올의정서
국내이행법령
사업안내
특정물질 수출입
알림·자료실
민원서비스
닫기